Enterprise Value
-338.4M
Cash
608.1M
Avg Qtr Burn
-22.19M
Short % of Float
2.57%
Insider Ownership
9.04%
Institutional Own.
74.22%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AT-527 (Bemnifosbuvir) Details Infectious disease, COVID-19 | Phase 3 Data readout | |
Bemnifosbuvir + Ruzasvir (RZR) Details Hepatitis C | Phase 2 Data readout | |
AT-752 Details Infectious disease, Dengue Fever | Failed Discontinued | |
Failed Discontinued |